NICE nod for AstraZeneca's Lynparza
Therapy treats patients with specific types of ovarian, fallopian tube or primary peritoneal cancer - News - PharmaTimes
Stay updated with breaking news from Ptom Keith Roach. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Therapy treats patients with specific types of ovarian, fallopian tube or primary peritoneal cancer - News - PharmaTimes
In final draft guidance, NICE has recommended dapagliflozin (Forxiga) for patients with heart failure regardless of ejection fraction.
With visions of the UK as a ‘life sciences superpower’ at risk, we report from Great Ormond Street hospital on what’s being done to give children access to new drugs
Decision will create opportunity for therapy to be used earlier in the treatment pathway - News - PharmaTimes
The Scottish Medicines Consortium has accepted fam-trastuzumab deruxtecan-nxki as a treatment option for adult patients with HER2-positive unresectable or metastatic breast cancer who have received 1 prior anti–HER2-based therapy.